Skip to content

Clinical trials

Glucose Metabolism Disorders trials with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Glucose Metabolism Disorders Phase: Not applicable Clear all

163 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20051
20071
20091
20103
20116
20123
201411
20159
201615
201717
201814
201915
20206
202110
20229
202317
202418
20253
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed106
Unknown status26
Recruiting12
Active, not recruiting8
Not yet recruiting3
Withdrawn3
Suspended2
Terminated2
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
University Hospital, Gentofte, Copenhagen8
Maastricht University Medical Center5
Steno Diabetes Center Copenhagen4
Hvidovre University Hospital3
University of Aarhus3
University of Cambridge3
University of Eastern Finland3
University of Missouri-Columbia3
Aarhus University Hospital2
Fractyl Health Inc.2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Glucose Metabolism Disorders163
Metabolic Diseases50
Endocrine System Diseases39
Diabetes Mellitus38
Diabetes Mellitus, Type 234
Insulin Resistance28
Obesity20
Glucose Intolerance17
Diabetes Mellitus, Type 116
Lipid Metabolism Disorders13

Trials

Showing 51 to 75 of 163. Each trial links to its page on Pharma Observatory.

63 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.